Buy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical Advancements

Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ARCT stock, giving a Buy rating yesterday.

Yanan Zhu has given his Buy rating due to a combination of factors including the anticipated revenue from Arcturus Therapeutics’ COVID-19 vaccine deliveries and potential commercial milestone payments. The company’s financial position appears robust, with sufficient cash on hand to operate through the early part of 2027, and they are on track to fulfill a significant delivery of 4 million doses of their COVID-19 vaccine, Kostaive, to Japan for the upcoming fall and winter season. This delivery is expected to trigger the first commercial milestone payments, providing a positive financial catalyst for the company.

Additionally, Zhu sees potential for further upside in the monetization of Arcturus’s ownership stake in the ARCALIS facility, considering the current investments and comparable transactions in the industry. Furthermore, the forthcoming data from phase 2 studies of ARCT-810 for OTCD and interim data for ARCT-032 for Cystic Fibrosis are expected to provide more insights into the company’s pipeline, thereby potentially strengthening the investment thesis. With these factors in mind, Zhu’s Buy rating reflects both the near-term financial prospects and the anticipated clinical advancements of Arcturus Therapeutics.

In another report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $140.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Arcturus Therapeutics (ARCT) Company Description:

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.